Growth / Performance
GHRP-6
C₄₆H₅₆N₁₂O₆
Key Research Findings
- One of the first synthetic GH secretagogues, establishing the GHRP research field.
- Significantly elevates appetite and food intake alongside GH secretion via ghrelin mimicry.
- Demonstrates cardioprotective effects in ischaemia-reperfusion animal models independent of GH.
- Raises cortisol and prolactin at higher doses — a distinguishing property from Ipamorelin.
Overview
GHRP-6 is a first-generation synthetic hexapeptide growth hormone releasing peptide that acts as a potent agonist of the ghrelin receptor (GHSR-1a). It was among the first GHRP compounds studied and remains a reference compound for GH secretagogue research.
Mechanism of Action
GHRP-6 activates GHSR-1a receptors both in the pituitary and hypothalamus, triggering GH release through a mechanism distinct from GHRH. It also strongly stimulates appetite via hypothalamic ghrelin pathways, a property that differentiates it from newer, more selective GHRPs like Ipamorelin.
Research Effects
GH Release
Extensive ResearchAmong the most well-characterised GH secretagogues; extensive animal and human dose-response data confirming GHSR-1a-mediated GH release.
Appetite Stimulation
Extensive ResearchStrong ghrelin-mimetic appetite stimulation is a well-documented and consistent finding across species.
IGF-1 Increase
Moderate ResearchSecondary to GH release; IGF-1 elevation mediates downstream anabolic effects in research models.
Cardioprotection
Moderate ResearchPre-clinical studies demonstrate GHRP-6 reduces cardiomyocyte apoptosis and infarct size in ischaemia-reperfusion models, via a GH-independent pathway.
Research Purposes Only — All information on this page is provided for scientific research purposes only. This product is not intended for human consumption, diagnosis, treatment, or prevention of any disease.
Quick Facts
Research Status Key
Related Peptides
Growth / Performance
CJC-1295 (No DAC)
CJC-1295 without DAC (also known as Modified GRF 1–29 or Mod GRF 1–29) is a 29-amino acid analogue of growth hormone-releasing hormone (GHRH). It contains four amino acid substitutions that increase its stability and receptor affinity compared to native GHRH, while the absence of the Drug Affinity Complex (DAC) preserves a shorter, more physiological half-life.
Learn More →
Growth / Performance
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist (GHSR-1a) consisting of 5 amino acids. It is studied for its highly selective GH-releasing properties, producing significant GH pulses without the concomitant cortisol, prolactin, or ACTH release seen with first-generation GHRPs.
Learn More →
Growth / Performance
Tesamorelin
Tesamorelin is a synthetic analogue of GHRH consisting of the full 44-amino acid sequence of native GHRH modified with a trans-3-hexenoic acid group at the N-terminus, enhancing stability. It is the only FDA-approved GHRH analogue, licensed for HIV-associated lipodystrophy treatment under the name Egrifta.
Learn More →